Clinical Trials

Kiadis Pharma has raised EUR10m in a financing round to conduct Phase II study of a cell based medicinal product candidate, ATIR, and to prepare a Phase II/III study. ATIR Phase II study is...

Pfizer Phase III study of pregabalin controlled-release (CR) formulation has met primary endpoint of time to loss of therapeutic response (LTR), in fibromyalgia patients. The primary endpoint of the placebo-controlled, multi-center study was achieved...

Idera Pharmaceuticals has concluded enrolling patients in double-blind, placebo-controlled Phase 2 trial assessing IMO-3100 in psoriasis patients. The study randomized 44 patients suffering from moderate to severe plaque psoriasis with IMO-3100 at 0.16mg/kg or...

Novavax A/H5N1 avian influenza vaccine candidate has met safety and immunogenicity endpoints in two Phase 1 clinical trials. The trials achieved the primary objectives by displaying the safety and immunogenicity of different doses of...

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the start of a phase II clinical trial of oral inecalcitol in...

Millennium Laboratories has commenced clinical outcomes study of its pharmacogenetic test. As part of the study, Millennium will evaluate the relationship between CYP genotype and clinical outcomes that include level of analgesia, functional status...

PhaseBio Pharmaceuticals has commenced patient dosing in a multicenter Phase 2b trial designed to evaluate the efficacy and safety of three doses of once weekly Glymera compared to matched placebo as well as an active comparator for the...